Surfing the MASH Tsunami
Driving the Discussion in Fatty Liver Disease. Join hepatology researcher and Key Opinion Leader Jörn Schattenberg, Liver Wellness Advocate Louise Campbell, and Forecasting and Pricing Guru Roger Green and a global group of Key Opinion Leaders and patient advocates as they discuss key issues in Fatty Liver disease, including epidemiology, drug development, clinical pathways, non-invasive testing, health economics and regulatory issues, from their own unique perspectives on the Surfing the MASH Tsunami podcast. #MASH #MAFLD #FattyLiver #livertwitter #AASLD #GlobalLiver #NoNASH #EASL
Surfing the MASH Tsunami
S4-E11.1 - The Surfers Highlight What’s Happening for Fatty Liver in 2023
The Surfers host a thought-provoking impromptu session on what’s happening thus far for the Fatty Liver field in 2023. Jörn Schattenberg leads this conversation with comments around diagnostic and therapeutic advancements following the momentum gathered at NASH-TAG in January. He points to the large number of abstracts (estimated at over 2500!) submitted to the upcoming EASL Congress held in Vienna this June. While drugs are leading the way, Jörn insists diagnostics are closely following and contributing to "excitement on both borders.” Roger Green notes activity around organizing trials that incorporate non-invasive endpoints.
Louise Campbell adds her highlight to be the recent AASLD guidance and its focus on clarifying CAP scores for improved FibroScan assessment. This is joint with eager anticipation of a NICE approval for access to FibroScan in the primary care setting. Roger comments on emerging competitor technologies, such as E-Scopics, and their influence on industry uptake of NITs. Combined with the various emerging guidelines and guidances, more doctors and specialties should begin focusing on how and when to test. Louise notes the potential challenges behind adopting liver-conscious practices for endocrinology and cardiology clinics in that there will be questions around how exactly this initiative is administered. However, these are exciting and surmountable challenges with rewarding implications. In Louise’s experience, “if you find real time with that person in the room, you can really make a change.” Roger connects these ideas around frontline screening to the podcast’s latest ventures in launching the Rising Tide series available at SurfingNASH.com. Lastly, he describes emerging energies around payer dynamics and drug utilization in the US.
If you enjoy the episode, have questions or interest around its contents and Fatty Liver disease, we kindly ask that you submit reviews wherever you download our discussions. Alternatively, you can write to us directly at questions@SurfingNASH.com.
Stay Safe and Surf On!